Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
3.850
+0.350 (10.00%)
At close: Dec 5, 2025, 4:00 PM EST
3.999
+0.149 (3.88%)
After-hours: Dec 5, 2025, 7:58 PM EST
Gain Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Gain Therapeutics stock have an average target of 8.00, with a low estimate of 6.00 and a high estimate of 12. The average target predicts an increase of 107.79% from the current stock price of 3.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 15, 2025.
Analyst Ratings
The average analyst rating for Gain Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 5 | 5 | 5 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +133.77% | Oct 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +107.79% | Oct 13, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $5 → $7 | Strong Buy | Maintains | $5 → $7 | +81.82% | Oct 7, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +133.77% | Sep 8, 2025 |
| Roth Capital | Roth Capital | Strong Buy Maintains $7 → $6 | Strong Buy | Maintains | $7 → $6 | +55.84% | Aug 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.66
from -0.89
EPS Next Year
-0.78
from -0.66
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.66 | -0.65 | ||
| Avg | -0.66 | -0.78 | ||
| Low | -0.65 | -0.93 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.